MANE · ISSUER CIK 1827635
Veradermics, Inc
Between Aug 1, 2026 and Oct 29, 2026, 5 Veradermics, Inc insiders reported $0.00 of open-market purchases and $103.1M of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$103.1MInsider selling
−$103.1MNet open-market
Sep 3, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 202616:35 | Sep 1, 2026 | MANE | Chief R&D Officer | A · Grant | — | +9,650 | 9,650 | New | — | ||
| Aug 21, 202618:11 | Aug 20, 2026 | MANE | Director · +3 joint | X · Exercise | — | +300,000 | 612,033 | +96% | — | ||
| Aug 21, 202618:11 | Aug 19, 2026 | MANE | Director · +3 joint | S · Sell | $107.25 | −750,000 | 461,033 | -62% | −$80.4M | ||
| Aug 18, 202621:10 | Aug 17, 2026 | MANE | Chief Technical Officer | S · Sell10b5-1 | $107.82 | −43,500 | 78,142 | -36% | −$4.7M | ||
| Aug 18, 202621:10 | Aug 17, 2026 | MANE | Chief Technical Officer | M · Exercise10b5-1 | $12.19 | +3,452 | 121,642 | +3% | $42K | ||
| Aug 18, 202621:04 | Aug 17, 2026 | MANE | Chief Executive Officer, Director | S · Sell10b5-1 | $107.86 | −67,500 | 170,824 | -28% | −$7.3M | ||
| Aug 18, 202621:04 | Aug 17, 2026 | MANE | Chief Executive Officer, Director | M · Exercise10b5-1 | $12.19 | +3,452 | 238,324 | +1% | $42K | ||
| Aug 14, 202618:01 | Aug 12, 2026 | MANE | Director | S · Sell | $107.12 | −100,000 | 194,117 | -34% | −$10.7M |